Non-antiarrhythmic pharmacotherapy in cardio-renal-metabolic disease and incident atrial fibrillation: a trial meta-analysis
Why the study?
Does non-antiarrhythmic pharmacotherapy reduce incident atrial fibrillation in patients with cardio-renal-metabolic disease?
Population
Patients with cardio-renal-metabolic disease
Design
Meta-analysis
Authors
Discussion
Loading...
Member takes
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Available data provide hypothesis-generating estimates that treatment of HFrEF with ACEi/ARB, MRA, and SGLT2 inhibitors, treatment of CKD with SGLT2 inhibitors, and treatment of obesity with GLP-1 RAs, may be associated with a relative risk reduction in incident AF.”
“Several commonly used drug classes for cardiometabolic conditions appear to influence AF risk — highlighting upstream prevention opportunities that extend beyond rhythm-control therapies.”
Overview
Should not yet change practice; leaves open whether cardio-renal-metabolic medications reduce incident AF pending trials with pre-specified AF outcomes.
Key Points
- Atrial fibrillation incidence may be affected by cardio-renal-metabolic treatments, as suggested by meta-analysis findings.
- Key evidence indicates the need for integration of potential AF outcomes in future prospective RCTs to clarify impacts on health.
- This assessment focuses on the association between pharmacotherapy and atrial fibrillation, highlighting its clinical relevance.
- Future research aims to integrate AF as a scheduled outcome in cardio-renal-metabolic medication trials to enhance understanding.
Structured PICO
Does non-antiarrhythmic pharmacotherapy reduce incident atrial fibrillation in patients with cardio-renal-metabolic disease?
P
Population
Patients with cardio-renal-metabolic disease
I
Intervention
Non-antiarrhythmic pharmacotherapy (cardio-renal-metabolic medications)
O
Outcome
Incident atrial fibrillation
The authors call for future trials of cardio-renal-metabolic medications to include incident atrial fibrillation as a pre-specified outcome.
Cite This Study
Raveendra et al. (2026) studied this question.